Moderna to Present at Upcoming Conferences in March 2025CAMBRIDGE, MA / ACCESS Newswire / February 25, 2025 / Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences:
Moderna Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business UpdatesReports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss includes approximately $0.2 billion of non-cash charges related to manufacturing resizing
Moderna to Report Fourth Quarter and Full Year 2024 Financial Results on Friday, February 14, 2025CAMBRIDGE, MA / ACCESS Newswire / January 29, 2025 / Moderna, Inc. (
NASDAQMRNA) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, February 14, 2025 to report its fourth quarter and full year 2024 financial results, and provide a corporate update.
Moderna Awarded Tender for the Supply of Its mRNA COVID-19 Vaccine in the European UnionThe Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats
Moderna Announces Updates on Pandemic Influenza ProgramCAMBRIDGE, MA / ACCESS Newswire / January 17, 2025 / Moderna, Inc. (
NASDAQMRNA) today announced ongoing support from the U.S. Department of Health and Human Services (HHS) to accelerate the development of mRNA-based pandemic influenza vaccines. The award was made through the Rapid Response Partnership Vehicle (RRPV) Consortium with funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Administration for Strategic Preparedness and Response (ASPR).
Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare ConferenceAchieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited)
Moderna to Present at Upcoming Conferences in December 2024CAMBRIDGE, MA / ACCESSWIRE / November 25, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences:
Moderna Receives Health Canada Approval for RSV Vaccine for Adults Aged 60 Years and OldermRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes
Moderna Tops BioSpace's Best Places to Work Ranking for Fourth Consecutive YearCAMBRIDGE, MA / ACCESSWIRE / November 12, 2024 / Moderna, Inc. (
NASDAQMRNA) today announced it was ranked the number one large employer in BioSpace's 2025 Best Places to Work report based on the Company's reputation and commitment to innovation.
Moderna Reports Third Quarter 2024 Financial Results and Provides Business UpdatesReports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03
Moderna to Present at Upcoming Conferences in November 2024CAMBRIDGE, MA / ACCESSWIRE / October 31, 2024 / Moderna, Inc. (
NASDAQMRNA), today announced its participation in the following upcoming investor conferences:
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
Merck (
NYSEMRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (Nasdaq: MRNA), today announced the initiation of INTerpath-009, a pivotal Phase 3 randomized clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resectable Stage II, IIIA or IIIB (N2) non-small cell lung cancer (NSCLC) who did not achieve a pathological complete response (pCR) after receiving neoadjuvant KEYTRUDA plus platinum-based chemotherapy. Global recruitment in INTerpath-009 has begun, and the first patients have now started enrolling in Canada.
Moderna Named a Top Employer by Science for Tenth Consecutive YearCAMBRIDGE, MA / ACCESSWIRE / October 24, 2024 / Moderna, Inc. (
NASDAQMRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2024 Top Employers Survey for the tenth consecutive year. Moderna was recognized for its commitment to continuous innovation, treating employees with respect, and social responsibility.
Abbas Hussain Joins Moderna's Board of DirectorsHussain brings more than 35 years of commercial leadership and operating experience in healthcare, most recently serving as CEO of Vifor Pharma
Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (
NASDAQMRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 7, 2024 to report its third quarter 2024 financial results, and provide a corporate update.
MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Moderna, Inc. (“Moderna” or “the Company”) (
NASDAQMRNA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
MRNA Deadline: Rosen Law Firm Urges Moderna, Inc. (NASDAQ: MRNA) Stockholders With Large Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of Moderna, Inc. (
NASDAQMRNA) between January 18, 2023 and June 25, 2024. Moderna describes itself as a “biotechnology company that discovers, develops, and commercializes messenger RNA (“mRNA”) therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the U.S., Europe, and internationally.”
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the FirmNEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Moderna, Inc. (
NASDAQMRNA), Lululemon Athletica Inc.
NASDAQ: LULUNASDAQLULU)
(NASDAQ: XPELNASDAQXPEL
, and Nano Nuclear Energy Inc. (NASDAQ: NNENASDAQ
). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the FirmNEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Moderna, Inc. (
NASDAQMRNA), Lululemon Athletica Inc.
NASDAQ: LULUNASDAQLULU)
(NASDAQ: XPELNASDAQXPEL
, and Nano Nuclear Energy Inc. (NASDAQ: NNENASDAQ
). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 VaccinesCAMBRIDGE, MA and TAIPEI, TAIWAN / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Cenra Healthcare, the sales and marketing arm of Cenra Inc., today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Taiwan, including Moderna's COVID-19 vaccine, Spikevax®.
Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (
NASDAQMRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized clinical trial evaluating the efficacy, safety, and immunogenicity of an investigational norovirus vaccine, mRNA-1403. Global recruitment for the Nova 301 trial has also begun.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the FirmNEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Moderna, Inc. (
NASDAQMRNA), Lululemon Athletica Inc.
NASDAQ: LULUNASDAQLULU)
(NASDAQ: XPELNASDAQXPEL
, and Nano Nuclear Energy Inc. (NASDAQ: NNENASDAQ
). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.
